[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Suxia Li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,60],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100626400","a-single-center-clinical-study-to-evaluate-the-efficacy-and-safety-of-autologous-urine-derived-epithelial-cells-in-the-treatment-of-corneal-endothelial-cell-dysfunction-100626400",false,"NCT07435142","A Single-Center Clinical Study to Evaluate the Efficacy and Safety of Autologous Urine-Derived Epithelial Cells in the Treatment of Corneal Endothelial Cell Dysfunction","Inclusion Criteria:\n\n1. Patients diagnosed with corneal endothelial cell dysfunction, including those with a history of at least one penetrating keratoplasty.\n2. Patients aged 18 years or older and 85 years or younger at the time of informed consent acquisition (regardless of gender).\n3. Patients with central corneal endothelial cell density below 500-800 cells\u002Fmm² or unmeasurable, as detected by corneal endothelial microscopy or confocal microscopy.\n4. Patients who can voluntarily participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients with unexplained keratoconjunctival diseases.\n2. Patients with active corneal infections or systemic infections (e.g., positive for bacteria, fungi, HBV, HCV, or other viruses).\n3. Patients with an intraocular pressure (IOP) of ≥30 mmHg (excluding those whose IOP can be controlled below 21 mmHg with glaucoma medications).\n4. Patients with neovascularization observed in the angle of the anterior chamber or who have undergone treatment for neovascular glaucoma.\n5. Patients with a history of allergies to drugs prescribed during the perioperative period and postoperative observation period \\[anesthetics (lidocaine injection), antibiotics (ofloxacin eye drops or ointment), steroid preparations (0.1% fluorometholone eye drops, tobramycin and dexamethasone eye drops or ointment, prednisolone acetate eye drops or ointment), glaucoma medications (prostaglandin preparations, β-blockers, carbonic anhydrase inhibitors, linezolid eye drops), etc.\\].\n6. Patients planning to undergo intraocular surgery during this clinical study.\n7. Diabetic patients with poor blood glucose control (HbA1C ≥8.5%).\n8. Patients with a history of cancer or\u002Fand with systemic autoimmune disease.\n9. Patients with severe liver dysfunction (AST\\>100 IU\u002FL or ALT\\>100 IU\u002FL).\n10. Patients with severe renal dysfunction requiring dialysis (serum creatinine ≥1.5 mg\u002Fdl).\n11. Patients with a systolic blood pressure of ≥180 mmHg or diastolic blood pressure of ≥110 mmHg despite antihypertensive treatment.\n12. Pregnant women, women possibly pregnant, or women planning pregnancy during this clinical study period.\n13. Patients unable to tolerate ophthalmic surgery under local anesthesia (e.g., severe claustrophobia).\n14. Patients who participated in other clinical trials or studies within 3 month prior to consent acquisition.\n15. Patients deemed unsuitable for this clinical study due to comorbidities, etc.","ALL","18 Years","85 Years",{"count":5,"type":19},"ESTIMATED","INTERVENTIONAL",[22],"NA","Corneal endothelial cell dysfunction is usually a corneal disease caused by damage or loss of corneal endothelial cells. It is characterized by corneal edema, opacity, and subepithelial bullae, leading to pain, blurred vision, or even blindness. Conventional treatments usually involve allogeneic corneal transplantation or corneal endothelial transplantation. Anterior chamber cell transplantation is a breakthrough treatment for corneal endothelial diseases developed in recent years. Autologous urine-derived epithelial cells greatly reduce the risk of immune rejection and the use of anti-rejection drugs, avoiding reliance on and waiting for corneal donors.",[25],"Cornea Disease","RECRUITING","2026-06-23",{"date":29,"type":30},"2026-06-26","ACTUAL",{"date":32,"type":30},"2026-02-21",{"date":34,"type":19},"2026-11-01",{"name":36,"class":37},"Suxia Li","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":47,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":4},"100642762","a-single-center-clinical-study-to-evaluate-the-efficacy-and-safety-of-sutureless-ophthalmic-hydrogel-for-corneal-wound-repair-100642762","NCT07638215","A Single-Center Clinical Study to Evaluate the Efficacy and Safety of Sutureless Ophthalmic Hydrogel for Corneal Wound Repair","Inclusion Criteria:\n\n* You must meet all the following inclusion criteria to participate in the study:\n\n  1. Patients with corneal stromal defects, including those caused by trauma or following lesion excision for infection, with a residual stromal thickness of ≥300 μm in the defect area.\n  2. Patients aged 18 to 85 years (inclusive, either sex) at the time of consent.\n  3. Patients who are capable of providing written informed consent voluntarily to participate in the study.\n\nExclusion Criteria:\n\n* You will be excluded from the study if you meet any of the following exclusion criteria:\n\n  1. Patients with unexplained keratoconjunctival diseases.\n  2. Patients with severe dry eye, symblepharon, corneal neovascularization, or other ocular surface disorders.\n  3. Patients with systemic infectious diseases (positive for bacteria\u002Ffungi\u002FHBV\u002FHCV\u002FHIV\u002FTP, etc.).\n  4. Patients with autoimmune diseases such as rheumatoid arthritis, Sjögren's syndrome, or graft-versus-host disease.\n  5. Patients with uncontrolled ocular diseases in the study eye.\n  6. Patients with major organ failure or other serious systemic conditions, including but not limited to cardiac insufficiency; poorly controlled diabetes mellitus (fasting blood glucose \\>8 mmol\u002FL despite glucose-lowering therapy); uncontrolled stage II or higher hypertension (blood pressure \\>160\u002F100 mmHg despite antihypertensive therapy); history of malignancy within the past 5 years; severe immunodeficiency, etc.\n  7. Patients with psychiatric disorders that may interfere with treatment or evaluation.\n  8. Pregnant or lactating women, or women planning to become pregnant during the clinical study.\n  9. Patients deemed unsuitable for participation in the clinical trial by the investigator.\n  10. Patients unable to complete follow-up visits.",{"count":46,"type":19},30,[22],"Corneal blindness is one of the leading causes of blindness worldwide. For various infectious and non-infectious corneal diseases, current clinical repair strategies include corneal lesion debridement, conjunctival flap coverage, amniotic membrane transplantation, corneal transplantation, contact lens application, and injectable sealants. Injectable hydrogels, as smart materials that transition from a liquid precursor to a solid gel in response to external stimuli (e.g., light, temperature, or chemical cross-linking), enable precise filling of corneal defects via minimally invasive injection. They offer superior morphological adaptability, conforming tightly to irregular wound surfaces and achieving sutureless closure. Moreover, they promote regenerative repair of the epithelium, stroma, and nerves, significantly reducing patient discomfort, infection risk, recovery time, and healthcare costs, thereby advancing the paradigm of corneal repair from \"transplant substitution\" to \"in situ regeneration.\"",[50],"Corenal Diseases","NOT_YET_RECRUITING","2026-06-04",{"date":54,"type":30},"2026-06-10",{"date":56,"type":19},"2026-05-22",{"date":58,"type":19},"2027-06-01",{"name":36,"class":37},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":66,"targetDuration":4,"studyType":20,"phases":68,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":76,"locationsCount":38},"100639690","a-single-center-clinical-study-to-evaluate-the-efficacy-and-safety-of-a-suture-free-ophthalmic-hydrogel-for-ocular-surface-tissue-adhesion-100639690","NCT07608367","A Single-Center Clinical Study to Evaluate the Efficacy and Safety of a Suture-Free Ophthalmic Hydrogel for Ocular Surface Tissue Adhesion","Inclusion Criteria:\n\n1. Patients with ocular surface diseases (e.g., pterygium, corneal ulcer, ocular surface burn, pseudopterygium, etc.) who need to undergo conjunctival flap adhesion, amniotic membrane transplantation, or keratoplasty.\n2. Aged 18 to 85 years old at the time of informed consent (regardless of gender).\n3. Able to provide written informed consent and voluntarily participate in the study.\n4. No severe systemic organic diseases, such as severe heart, liver, kidney diseases, and malignant tumors.\n\nExclusion Criteria:\n\n1. A history of allergy to the components of the suture-free ophthalmic hydrogel (e.g., decellularized porcine corneal matrix, GelMA, etc.) or the drugs prescribed during the perioperative and postoperative observation periods (anesthetics, antibiotics, steroid preparations, etc.).\n2. Patients with systemic infectious diseases (bacterial, fungal, positive for HBV, HCV and other viruses, etc.).\n3. Diabetic patients with poor blood glucose control (HbA1C ≥ 8.0%).\n4. Pregnant women, women who may be pregnant, or women planning to become pregnant during the clinical study.\n5. Patients who have participated in other clinical trials or studies within 1 month before obtaining informed consent.\n6. Other patients deemed unsuitable for the clinical study due to comorbidities.",{"count":67,"type":19},20,[22],"When severe ocular surface lesions occur (e.g., pterygium, corneal ulcer, ocular surface burn, etc.), the currently clinically common surgical procedures such as conjunctival flap coverage, amniotic membrane transplantation, and keratoplasty are primarily fixed by suturing. However, suturing has numerous drawbacks. On the one hand, the suturing process causes additional mechanical damage to ocular surface tissues, triggers local inflammatory responses, and increases postoperative discomfort such as pain and foreign body sensation. Moreover, uneven suture tension is prone to cause conjunctival flap shrinkage or displacement, impairing the repair effect. On the other hand, postoperative suture irritation continuously activates fibroblast proliferation, leading to excessive deposition of subconjunctival collagen and the formation of dense scar tissue, which in turn compromises the stability of the ocular surface tear film and visual quality. This study intends to develop a suture-free ophthalmic hydrogel for conjunctival flap adhesion. By combining the natural biological activity of decellularized porcine corneal matrix with the photocrosslinking properties of GelMA, and integrating low-energy visible light (465nm) curing technology, the hydrogel enables rapid, firm, and suture-free adhesion of conjunctival flaps.",[25],"2026-05-20",{"date":73,"type":30},"2026-05-27",{"date":56,"type":19},{"date":58,"type":19},{"name":36,"class":37},""]